Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of
GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to
patients with advanced or metastatic non-small cell lung cancer.